Topiramate safe, effective for migraine prevention. (Two Randomized Trials).

Publication: Internal Medicine News

Publication Date: 15-JUN-03

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2003 International Medical News Group

HONOLULU -- Topiramate, previously approved as an adjunctive therapy for a variety of seizure types, appears to be safe and effective in the prevention of migrame headaches, according to two studies presented at the annual meeting of the American Academy of Neurology.

One efficacy study, dubbed MIGR-001, involved 487 patients and was presented by Dr. David Dodick of the Mayo Clinic Scottsdale (Ariz.). The second, MIGR002, involved 483 patients and was presented by Dr. Jan L. Brandes of the Nashville (Tenn.) Neuroscience Group.

All patients had a history of migraine with or without aura, were 12-65 years of age, and had between 3 and 12 migraines per month, with no more than 15 headache days per month. They were randomized to receive placebo or doses of topiramate of 50 mg, 100 mg, or 200 mg/day (titrated from 25 mg/day) for 26 weeks.

Patients...

Read the full article for free courtesy of your local library.